Literature DB >> 27320318

TMPRSS2:ERG fusion gene occurs less frequently in Chinese patients with prostate cancer.

Hui Jiang1,2, Xueying Mao3, Xiaoyi Huang1, Jing Zhao1, Lumei Wang4, Jingjing Xu1, Hongwei Zhang5, Yongjie Lu4, Yongwei Yu6.   

Abstract

Prostate cancer is the commonest male malignancy in the Western world, but its morbidity is much lower in China. The principal aim of this study was to evaluate the frequency of TMPRSS2:ERG fusion in Chinese prostate cancer patients using immunohistochemistry and reverse transcription polymerase chain (RT-PCR). In addition, we compared the ERG protein expression with TMPRSS2:ERG fusion gene. The relationship between ERG expression and clinicopathologic features was also examined. Samples from patients who underwent radical prostatectomies in Changhai Hospital (Shanghai, China) were collected and stored in ethically approved tissue banks. One hundred seventy-four prostate cancer tissue samples and 10 normal tissues were marked on standard hematoxylin-eosin (HE) sections, punched out of the paraffin blocks and inserted into a recipient block using tissue arrayer instruments. Immunohistochemistry and RT-PCR were employed to detect TMPRSS2:ERG fusion gene. ERG was highly expressed in the nuclei of endothelial cells of vessels and weak cytoplasmic staining was occasionally observed. ERG positive staining was present in 14.9 % (26/174) of the tumor samples in microarray. All benign prostate samples were found to be negative. RT-PCR results revealed that 11.1 % (15/135) were TMPRSS2:ERG fusion positive. Altogether, there was a good agreement of ERG immunostaining with the presence of TMPRSS2:ERG. However, no correlation was observed between ERG expression and age, Gleason score, stage, surgical margin, and seminal vesicle involvement in Chinese patients. In the present study, we identified a high correlation between ERG expression and ERG TMPRSS2:ERG, with 100 % sensitivity and 88.9 % specificity. The expression level of ERG was unrelated to the age, Gleason score, stage, surgical margin, and seminal vesicle involvement. Therefore, the association between ERG expression and prostate cancer based on Chinese population should be further investigated in the future.

Entities:  

Keywords:  Chinese; Diagnosis; Immunohistochemistry; Prostate cancer; TMPRSS2:ERG

Mesh:

Substances:

Year:  2016        PMID: 27320318     DOI: 10.1007/s13277-016-5116-9

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  42 in total

1.  TMPRSS2:ETS fusions and clinicopathologic characteristics of prostate cancer patients from Eastern China.

Authors:  Jun Dong; Li Xiao; Lu Sheng; Jun Xu; Zhong-Quan Sun
Journal:  Asian Pac J Cancer Prev       Date:  2014

2.  Detection of TMPRSS2-ETS fusions by a multiprobe fluorescence in situ hybridization assay for the early diagnosis of prostate cancer: a pilot study.

Authors:  Qi-Peng Sun; Liao-Yuan Li; Zhong Chen; Jun Pang; Wei-Jiao Yang; Xiang-Fu Zhou; Jian-Guang Qiu; Zu-Lan Su; Dan He; Xin Gao
Journal:  J Mol Diagn       Date:  2010-07-08       Impact factor: 5.568

3.  A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis.

Authors:  Jacques Lapointe; Young H Kim; Melinda A Miller; Chunde Li; Gulsah Kaygusuz; Matt van de Rijn; David G Huntsman; James D Brooks; Jonathan R Pollack
Journal:  Mod Pathol       Date:  2007-03-02       Impact factor: 7.842

4.  TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia.

Authors:  Kyung Park; James T Dalton; Ramesh Narayanan; Christopher E Barbieri; Michael L Hancock; David G Bostwick; Mitchell S Steiner; Mark A Rubin
Journal:  J Clin Oncol       Date:  2013-12-02       Impact factor: 44.544

5.  Interracial differences in prostate cancer progression among patients from the United States, China and Japan.

Authors:  Haiyen E Zhau; Qinlong Li; Leland W K Chung
Journal:  Asian J Androl       Date:  2013-07-22       Impact factor: 3.285

6.  Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer.

Authors:  Rohit Mehra; Scott A Tomlins; Jianjun Yu; Xuhong Cao; Lei Wang; Anjana Menon; Mark A Rubin; Kenneth J Pienta; Rajal B Shah; Arul M Chinnaiyan
Journal:  Cancer Res       Date:  2008-05-15       Impact factor: 12.701

Review 7.  The impact of translocations and gene fusions on cancer causation.

Authors:  Felix Mitelman; Bertil Johansson; Fredrik Mertens
Journal:  Nat Rev Cancer       Date:  2007-03-15       Impact factor: 60.716

8.  Racial Variations in Prostate Cancer Molecular Subtypes and Androgen Receptor Signaling Reflect Anatomic Tumor Location.

Authors:  Farzana A Faisal; Debasish Sundi; Jeffrey J Tosoian; Voleak Choeurng; Mohammed Alshalalfa; Ashley E Ross; Eric Klein; Robert Den; Adam Dicker; Nicholas Erho; Elai Davicioni; Tamara L Lotan; Edward M Schaeffer
Journal:  Eur Urol       Date:  2015-10-09       Impact factor: 20.096

9.  [Frequency and transcript variant analysis of gene fusions between TMPRSS2 and ETS transcription factor genes in prostate cancer].

Authors:  Mei-Jie Dai; Li-Li Chen; Yan-Bo Zheng; Wei Chen; Zhi-Hua Tao; Zhi-Liang Weng; Xiu-Ling Wu; Cheng-Di Li; Zhan-Guo Chen; Xiao-Dong Chen; Shao-Bo Shi
Journal:  Zhonghua Yi Xue Za Zhi       Date:  2008-03-11

10.  Overexpression of ERG and Wild-Type PTEN Are Associated with Favorable Clinical Prognosis and Low Biochemical Recurrence in Prostate Cancer.

Authors:  Sung Han Kim; Soo Hee Kim; Jae Young Joung; Geon Kook Lee; Eun Kyung Hong; Kyung Min Kang; Ami Yu; Byung Ho Nam; Jinsoo Chung; Ho Kyung Seo; Weon Seo Park; Kang Hyun Lee
Journal:  PLoS One       Date:  2015-04-21       Impact factor: 3.240

View more
  7 in total

1.  Molecular characterization of prostate cancer in Middle Eastern population highlights differences with Western populations with prognostic implication.

Authors:  Ramy A Abdelsalam; Ibrahim Khalifeh; Alan Box; Maria Kalantarian; Sunita Ghosh; Hatem Abou-Ouf; Tamara Lotfi; Mohammed Shahait; Nallasivam Palanisamy; Tarek A Bismar
Journal:  J Cancer Res Clin Oncol       Date:  2020-04-30       Impact factor: 4.553

Review 2.  Ethnicity and ERG frequency in prostate cancer.

Authors:  Jason Sedarsky; Michael Degon; Shiv Srivastava; Albert Dobi
Journal:  Nat Rev Urol       Date:  2017-09-05       Impact factor: 14.432

3.  Prostate cancer in Jordanian-Arab population: ERG status and relationship with clinicopathologic characteristics.

Authors:  Najla Aldaoud; Nour Abdo; Samir Al Bashir; Mohammad Alqudah; Noor Marji; Hiba Alzou'bi; Rami Alazab; Kiril Trpkov
Journal:  Virchows Arch       Date:  2017-05-26       Impact factor: 4.064

4.  Expression of ERG Protein and TMRPSS2-ERG Fusion in Prostatic Carcinoma in Egyptian Patients.

Authors:  Ahmed Abdel-Hady; Ali El-Hindawi; Olfat Hammam; Heba Khalil; Sara Diab; Soulafa Abd El-Aziz; Mohamed Badawy; Ahmed Ismail; Noha Helmy; Nora Kamel; Shady Anis; Amr El Kholy; Khalid Al Osili; Afaf Abdel-Hady; Hani Nour; Maha Akl
Journal:  Open Access Maced J Med Sci       Date:  2017-03-20

Review 5.  Urinary markers aiding in the detection and risk stratification of prostate cancer.

Authors:  Nicholas Raja; Christopher M Russell; Arvin K George
Journal:  Transl Androl Urol       Date:  2018-09

6.  Prevalence and clinical application of TMPRSS2-ERG fusion in Asian prostate cancer patients: a large-sample study in Chinese people and a systematic review.

Authors:  De-Pei Kong; Rui Chen; Chun-Lei Zhang; Wei Zhang; Guang-An Xiao; Fu-Bo Wang; Na Ta; Xu Gao; Ying-Hao Sun
Journal:  Asian J Androl       Date:  2020 Mar-Apr       Impact factor: 3.285

7.  TMPRSS2: Potential Biomarker for COVID-19 Outcomes.

Authors:  Jonathan D Strope; Cindy H Chau PharmD; William D Figg
Journal:  J Clin Pharmacol       Date:  2020-05-21       Impact factor: 2.860

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.